UK Prescription Weight Loss Medications Market Size, Share & Trends Analysis Report By Product (Incretin-Based Therapies For Weight Management), By Route Of Administration (Injectable, Oral), By Prescribing Channel, And Segment Forecasts, 2026 - 2033
Summary
The UK prescription weight loss medications market size was estimated at USD 421.07 million in 2025 and is projected to reach USD 2,485.23 million by 2033, growing at a CAGR of 24.85% from 2026 to 2033. Growth is driven by rising obesity prevalence, increasing clinical adoption of incretin-based therapies, expanding access through private and digital prescribing channels, and growing patient awareness.
The UK prescription weight loss medications market is currently influenced by several key factors. The prevalence of obesity and overweight individuals in the country is a significant driver, as data from March 2025 indicate that approximately 64% of adults in England are classified as overweight or obese, with 29% meeting the criteria for obesity (BMI =30 kg/m?).
This large and persistent portion of the population creates a steady demand for weight-management solutions, particularly prescription-based treatments, as individuals increasingly seek alternatives to lifestyle changes such as diet and exercise. Obesity is often linked to various comorbidities such as type 2 diabetes, cardiovascular disease, and hypertension, further elevating the need for effective pharmacological treatments. As the population dealing with these health issues continues to grow, the demand for prescription weight loss medications is expected to rise, creating a sustainable market base for these treatments.
Another important factor is the shift in the regulatory and public-health environment, which has facilitated the adoption of pharmacological solutions. Notably, in 2023, the National Institute for Health and Care Excellence (NICE) approved Semaglutide (Wegovy) for managing obesity, and in late 2024, it extended approval to Tirzepatide (Mounjaro). These regulatory endorsements have made obesity treatment more accessible under the public healthcare system. As of early 2025, approximately 344,927 patients in England received licensed weight-loss medications under the NHS, marking a significant step toward integrating pharmacological treatments into routine healthcare. This trend is expected to continue as NICE guidelines evolve and more medications are approved for obesity management. The formal recognition of obesity as a medical condition that requires pharmacological intervention is not only improving access but also instilling confidence among patients and healthcare providers in the long-term use of these drugs.
The rapid uptake of effective medications, particularly GLP-1 receptor agonists like Semaglutide and Tirzepatide, has shifted the competitive landscape in the UK. These medications offer significant weight loss results, with clinical trials demonstrating body weight reductions of 15-20% when combined with lifestyle interventions. By 2025, prescribing volumes for GLP-1-based weight-loss medications surpassed those of older treatments, such as Orlistat, indicating a clear preference for these more effective options. However, uptake within the public healthcare system remains limited due to eligibility criteria and phased rollout. Consequently, a large number of patients are turning to private healthcare providers to access these medications. This has led to the growth of the private sector, where demand for weight-loss medications is high, driven by patients who seek effective treatments even when they do not meet NHS eligibility thresholds. This growing private sector represents a significant market opportunity, especially as more individuals opt to pay for faster access to these treatments, reflecting the evolving demand for weight-loss solutions in the UK.
UK Prescription Weight Loss Medications Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the UK prescription weight loss medications market report based on product, route of administration, and prescribing channel:
This report can be delivered to the clients within 1 Business Day
The UK prescription weight loss medications market size was estimated at USD 421.07 million in 2025 and is projected to reach USD 2,485.23 million by 2033, growing at a CAGR of 24.85% from 2026 to 2033. Growth is driven by rising obesity prevalence, increasing clinical adoption of incretin-based therapies, expanding access through private and digital prescribing channels, and growing patient awareness.
The UK prescription weight loss medications market is currently influenced by several key factors. The prevalence of obesity and overweight individuals in the country is a significant driver, as data from March 2025 indicate that approximately 64% of adults in England are classified as overweight or obese, with 29% meeting the criteria for obesity (BMI =30 kg/m?).
This large and persistent portion of the population creates a steady demand for weight-management solutions, particularly prescription-based treatments, as individuals increasingly seek alternatives to lifestyle changes such as diet and exercise. Obesity is often linked to various comorbidities such as type 2 diabetes, cardiovascular disease, and hypertension, further elevating the need for effective pharmacological treatments. As the population dealing with these health issues continues to grow, the demand for prescription weight loss medications is expected to rise, creating a sustainable market base for these treatments.
Another important factor is the shift in the regulatory and public-health environment, which has facilitated the adoption of pharmacological solutions. Notably, in 2023, the National Institute for Health and Care Excellence (NICE) approved Semaglutide (Wegovy) for managing obesity, and in late 2024, it extended approval to Tirzepatide (Mounjaro). These regulatory endorsements have made obesity treatment more accessible under the public healthcare system. As of early 2025, approximately 344,927 patients in England received licensed weight-loss medications under the NHS, marking a significant step toward integrating pharmacological treatments into routine healthcare. This trend is expected to continue as NICE guidelines evolve and more medications are approved for obesity management. The formal recognition of obesity as a medical condition that requires pharmacological intervention is not only improving access but also instilling confidence among patients and healthcare providers in the long-term use of these drugs.
The rapid uptake of effective medications, particularly GLP-1 receptor agonists like Semaglutide and Tirzepatide, has shifted the competitive landscape in the UK. These medications offer significant weight loss results, with clinical trials demonstrating body weight reductions of 15-20% when combined with lifestyle interventions. By 2025, prescribing volumes for GLP-1-based weight-loss medications surpassed those of older treatments, such as Orlistat, indicating a clear preference for these more effective options. However, uptake within the public healthcare system remains limited due to eligibility criteria and phased rollout. Consequently, a large number of patients are turning to private healthcare providers to access these medications. This has led to the growth of the private sector, where demand for weight-loss medications is high, driven by patients who seek effective treatments even when they do not meet NHS eligibility thresholds. This growing private sector represents a significant market opportunity, especially as more individuals opt to pay for faster access to these treatments, reflecting the evolving demand for weight-loss solutions in the UK.
UK Prescription Weight Loss Medications Market Report Segmentation
This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the UK prescription weight loss medications market report based on product, route of administration, and prescribing channel:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Incretin-Based Therapies for Weight Management
- Approved for Weight Loss
- Semaglutide (Wegovy)
- Liraglutide (Saxenda)
- Approved for Other Indications but Used Off-Label for Weight Loss
- Semaglutide (Ozempic)
- Tirzepatide (Mounjaro)
- Dulaglutide (Trulicity)
- oral semaglutide (Rybelsus)
- Oral GLP-1 & Incretin Therapies (Expected Market Entry)
- Oral Semaglutide (50 mg obesity dose) - expected 2026-2027
- Orforglipron (non-peptide oral GLP-1 RA) - expected 2027-2028
- Amycretin (oral GLP-1 analog) - pipeline (forecast scenario)
- Dual / Multi-Agonists (High-Impact Future Therapies)
- Tirzepatide (Zepbound) - Injectable (obesity approved US; UK expected)
- Retatrutide - Injectable (GLP 1/GIP/Glucagon triple agonist)
- Cagrisema (Cagrilintide + Semaglutide) - Injectable
- Survodutide (BI 456906) - Injectable (GLP 1/Glucagon dual agonist)
- Pemvidutide - Injectable (GLP-1/Glucagon)
- Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents)
- Lipase Inhibitors (Orlistat)
- Centrally Acting Agents (Bupropion/Naltrexone (Mysimba) - licensed in EU/UK for WL)
- Route Of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Injectable Weight Loss Medications
- Oral Weight Loss Medications
- Prescribing Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Public (NHS)
- NHS Primary Care Prescriptions
- NHS Specialist / Hospital Prescriptions
- Private
- Private (In-clinic) Prescriptions
- Digital / Online Prescribing Platforms
This report can be delivered to the clients within 1 Business Day
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Prescribing Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR?s Internal Database
1.5.3. Secondary Route of Administrations
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Route of Administrations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter?s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Incretin-Based Therapies for Weight Management
4.4.1. Incretin-Based Therapies for Weight Management Market, 2021 - 2033 (USD Million)
4.4.1.1. Approved for Weight Loss Market, 2021 - 2033 (USD Million)
4.4.1.1.1. Semaglutide (Wegovy) Market, 2021 - 2033 (USD Million)
4.4.1.1.2. Liraglutide (Saxenda) Market, 2021 - 2033 (USD Million)
4.4.1.2. Approved for Other Indications but Used Off-Label for Weight Loss Market, 2021 - 2033 (USD Million)
4.4.1.2.1. Semaglutide (Ozempic) Market, 2021 - 2033 (USD Million)
4.4.1.2.2. Tirzepatide (Mounjaro) Market, 2021 - 2033 (USD Million)
4.4.1.2.3. Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
4.4.1.2.4. oral semaglutide (Rybelsus) Market, 2021 - 2033 (USD Million)
4.4.1.3. Oral GLP-1 & Incretin Therapies (Expected Market Entry) Market, 2021 - 2033 (USD Million)
4.4.1.3.1. Oral Semaglutide (50 mg obesity dose) - expected 2026-2027 Market, 2021 - 2033 (USD Million)
4.4.1.3.2. Orforglipron (non-peptide oral GLP-1 RA) - expected 2027-2028 Market, 2021 - 2033 (USD Million)
4.4.1.3.3. Amycretin (oral GLP-1 analog) - pipeline (forecast scenario) Market, 2021 - 2033 (USD Million)
4.4.1.4. Dual / Multi-Agonists (High-Impact Future Therapies) Market, 2021 - 2033 (USD Million)
4.4.1.4.1. Tirzepatide (Zepbound) - Injectable (obesity approved US; UK expected) Market, 2021 - 2033 (USD Million)
4.4.1.4.2. Retatrutide - Injectable (GLP 1/GIP/Glucagon triple agonist) Market, 2021 - 2033 (USD Million)
4.4.1.4.3. Cagrisema (Cagrilintide + Semaglutide) - Injectable Market, 2021 - 2033 (USD Million)
4.4.1.4.4. Survodutide (BI 456906) - Injectable (GLP 1/Glucagon dual agonist) Market, 2021 - 2033 (USD Million)
4.4.1.4.5. Pemvidutide - Injectable (GLP-1/Glucagon) Market, 2021 - 2033 (USD Million)
4.5. Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents)
4.5.1. Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents) Market, 2021 - 2033 (USD Million)
4.5.1.1. Lipase Inhibitors (Orlistat) Market, 2021 - 2033 (USD Million)
4.5.1.2. Centrally Acting Agents (Bupropion/Naltrexone (Mysimba) - licensed in EU/UK for WL) Market, 2021 - 2033 (USD Million)
CHAPTER 5. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2025 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
5.4. Injectable Weight Loss Medications
5.4.1. Injectable Weight Loss Medications Market, 2021 - 2033 (USD Million)
5.5. Oral Weight Loss Medications
5.5.1. Oral Weight Loss Medications Market, 2021 - 2033 (USD Million)
CHAPTER 6. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: PRESCRIBING CHANNEL BUSINESS ANALYSIS
6.1. Prescribing Channel Market Share, 2025 & 2033
6.2. Prescribing Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Prescribing Channel, 2021 to 2033 (USD Million)
6.4. Public (NHS)
6.4.1. Public (NHS) Market, 2021 - 2033 (USD Million)
6.4.1.1. NHS Primary Care Prescriptions Market, 2021 - 2033 (USD Million)
6.4.1.2. NHS Specialist / Hospital Prescriptions Market, 2021 - 2033 (USD Million)
6.5. Private
6.5.1. Private Market, 2021 - 2033 (USD Million)
6.5.1.1. Private (In-clinic) Prescriptions Market, 2021 - 2033 (USD Million)
6.5.1.2. Digital / Online Prescribing Platforms Market, 2021 - 2033 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Novo Nordisk
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Eli Lilly
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. F. Hoffmann-La Roche
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. GSK
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Sanofi
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. AstraZeneca
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Teva Pharmaceutical Industries
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Sandoz
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Viatris
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Prescribing Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR?s Internal Database
1.5.3. Secondary Route of Administrations
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Route of Administrations
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter?s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
CHAPTER 4. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: PRODUCT BUSINESS ANALYSIS
4.1. Product Market Share, 2025 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Incretin-Based Therapies for Weight Management
4.4.1. Incretin-Based Therapies for Weight Management Market, 2021 - 2033 (USD Million)
4.4.1.1. Approved for Weight Loss Market, 2021 - 2033 (USD Million)
4.4.1.1.1. Semaglutide (Wegovy) Market, 2021 - 2033 (USD Million)
4.4.1.1.2. Liraglutide (Saxenda) Market, 2021 - 2033 (USD Million)
4.4.1.2. Approved for Other Indications but Used Off-Label for Weight Loss Market, 2021 - 2033 (USD Million)
4.4.1.2.1. Semaglutide (Ozempic) Market, 2021 - 2033 (USD Million)
4.4.1.2.2. Tirzepatide (Mounjaro) Market, 2021 - 2033 (USD Million)
4.4.1.2.3. Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
4.4.1.2.4. oral semaglutide (Rybelsus) Market, 2021 - 2033 (USD Million)
4.4.1.3. Oral GLP-1 & Incretin Therapies (Expected Market Entry) Market, 2021 - 2033 (USD Million)
4.4.1.3.1. Oral Semaglutide (50 mg obesity dose) - expected 2026-2027 Market, 2021 - 2033 (USD Million)
4.4.1.3.2. Orforglipron (non-peptide oral GLP-1 RA) - expected 2027-2028 Market, 2021 - 2033 (USD Million)
4.4.1.3.3. Amycretin (oral GLP-1 analog) - pipeline (forecast scenario) Market, 2021 - 2033 (USD Million)
4.4.1.4. Dual / Multi-Agonists (High-Impact Future Therapies) Market, 2021 - 2033 (USD Million)
4.4.1.4.1. Tirzepatide (Zepbound) - Injectable (obesity approved US; UK expected) Market, 2021 - 2033 (USD Million)
4.4.1.4.2. Retatrutide - Injectable (GLP 1/GIP/Glucagon triple agonist) Market, 2021 - 2033 (USD Million)
4.4.1.4.3. Cagrisema (Cagrilintide + Semaglutide) - Injectable Market, 2021 - 2033 (USD Million)
4.4.1.4.4. Survodutide (BI 456906) - Injectable (GLP 1/Glucagon dual agonist) Market, 2021 - 2033 (USD Million)
4.4.1.4.5. Pemvidutide - Injectable (GLP-1/Glucagon) Market, 2021 - 2033 (USD Million)
4.5. Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents)
4.5.1. Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents) Market, 2021 - 2033 (USD Million)
4.5.1.1. Lipase Inhibitors (Orlistat) Market, 2021 - 2033 (USD Million)
4.5.1.2. Centrally Acting Agents (Bupropion/Naltrexone (Mysimba) - licensed in EU/UK for WL) Market, 2021 - 2033 (USD Million)
CHAPTER 5. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: ROUTE OF ADMINISTRATION BUSINESS ANALYSIS
5.1. Route of Administration Market Share, 2025 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
5.4. Injectable Weight Loss Medications
5.4.1. Injectable Weight Loss Medications Market, 2021 - 2033 (USD Million)
5.5. Oral Weight Loss Medications
5.5.1. Oral Weight Loss Medications Market, 2021 - 2033 (USD Million)
CHAPTER 6. UK PRESCRIPTION WEIGHT LOSS MEDICATIONS MARKET: PRESCRIBING CHANNEL BUSINESS ANALYSIS
6.1. Prescribing Channel Market Share, 2025 & 2033
6.2. Prescribing Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Prescribing Channel, 2021 to 2033 (USD Million)
6.4. Public (NHS)
6.4.1. Public (NHS) Market, 2021 - 2033 (USD Million)
6.4.1.1. NHS Primary Care Prescriptions Market, 2021 - 2033 (USD Million)
6.4.1.2. NHS Specialist / Hospital Prescriptions Market, 2021 - 2033 (USD Million)
6.5. Private
6.5.1. Private Market, 2021 - 2033 (USD Million)
6.5.1.1. Private (In-clinic) Prescriptions Market, 2021 - 2033 (USD Million)
6.5.1.2. Digital / Online Prescribing Platforms Market, 2021 - 2033 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Novo Nordisk
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Eli Lilly
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. F. Hoffmann-La Roche
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. GSK
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Sanofi
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. AstraZeneca
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Teva Pharmaceutical Industries
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Sandoz
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Viatris
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
LIST OF TABLES
Table 1 List of secondary route of administrations
Table 2 List of abbreviations
Table 3 UK prescription weight loss medications market, by product, 2021 - 2033 (USD Million)
Table 4 UK prescription weight loss medications market, by route of administration, 2021 - 2033 (USD Million)
Table 5 UK prescription weight loss medications market, by prescribing channel, 2021 - 2033 (USD Million)
Table 1 List of secondary route of administrations
Table 2 List of abbreviations
Table 3 UK prescription weight loss medications market, by product, 2021 - 2033 (USD Million)
Table 4 UK prescription weight loss medications market, by route of administration, 2021 - 2033 (USD Million)
Table 5 UK prescription weight loss medications market, by prescribing channel, 2021 - 2033 (USD Million)
LIST OF FIGURES
Fig. 1 UK prescription weight loss medications market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and product outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 UK prescription weight loss medications market dynamics
Fig. 12 UK prescription weight loss medications market: Porter?s five forces analysis
Fig. 13 UK prescription weight loss medications market: PESTLE analysis
Fig. 14 Incretin-Based Therapies for Weight Management Market, 2021 - 2033 (USD Million)
Fig. 15 Approved for Weight Loss Market, 2021 - 2033 (USD Million)
Fig. 16 Semaglutide (Wegovy) Market, 2021 - 2033 (USD Million)
Fig. 17 Liraglutide (Saxenda) Market, 2021 - 2033 (USD Million)
Fig. 18 Approved for Other Indications but Used Off-Label for Weight Loss Market, 2021 - 2033 (USD Million)
Fig. 19 Semaglutide (Ozempic) Market, 2021 - 2033 (USD Million)
Fig. 20 Tirzepatide (Mounjaro) Market, 2021 - 2033 (USD Million)
Fig. 21 Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
Fig. 22 oral semaglutide (Rybelsus) Market, 2021 - 2033 (USD Million)
Fig. 23 Oral GLP-1 & Incretin Therapies (Expected Market Entry) Market, 2021 - 2033 (USD Million)
Fig. 24 Oral Semaglutide (50 mg obesity dose) - expected 2026-2027 Market, 2021 - 2033 (USD Million)
Fig. 25 Orforglipron (non-peptide oral GLP-1 RA) - expected 2027-2028 Market, 2021 - 2033 (USD Million)
Fig. 26 Amycretin (oral GLP-1 analog) - pipeline (forecast scenario) Market, 2021 - 2033 (USD Million)
Fig. 27 Dual / Multi-Agonists (High-Impact Future Therapies) Market, 2021 - 2033 (USD Million)
Fig. 28 Tirzepatide (Zepbound) - Injectable (obesity approved US; UK expected) Market, 2021 - 2033 (USD Million)
Fig. 29 Retatrutide - Injectable (GLP 1/GIP/Glucagon triple agonist) Market, 2021 - 2033 (USD Million)
Fig. 30 Cagrisema (Cagrilintide + Semaglutide) - Injectable Market, 2021 - 2033 (USD Million)
Fig. 31 Survodutide (BI 456906) - Injectable (GLP 1/Glucagon dual agonist) Market, 2021 - 2033 (USD Million)
Fig. 32 Pemvidutide - Injectable (GLP-1/Glucagon) Market, 2021 - 2033 (USD Million)
Fig. 33 Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents) Market, 2021 - 2033 (USD Million)
Fig. 34 Lipase Inhibitors (Orlistat) Market, 2021 - 2033 (USD Million)
Fig. 35 Centrally Acting Agents (Bupropion/Naltrexone (Mysimba) - licensed in EU/UK for WL) Market, 2021 - 2033 (USD Million)
Fig. 36 Injectable Weight Loss Medications Market, 2021 - 2033 (USD Million)
Fig. 37 Oral Weight Loss Medications Market, 2021 - 2033 (USD Million)
Fig. 38 Public (NHS) Market, 2021 - 2033 (USD Million)
Fig. 39 NHS Primary Care Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 40 NHS Specialist / Hospital Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 41 Private Market, 2021 - 2033 (USD Million)
Fig. 42 Private (In-clinic) Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 43 Digital / Online Prescribing Platforms Market, 2021 - 2033 (USD Million)
Fig. 44 Company categorization
Fig. 45 Company market position analysis
Fig. 46 Strategic framework
Fig. 1 UK prescription weight loss medications market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and product outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 UK prescription weight loss medications market dynamics
Fig. 12 UK prescription weight loss medications market: Porter?s five forces analysis
Fig. 13 UK prescription weight loss medications market: PESTLE analysis
Fig. 14 Incretin-Based Therapies for Weight Management Market, 2021 - 2033 (USD Million)
Fig. 15 Approved for Weight Loss Market, 2021 - 2033 (USD Million)
Fig. 16 Semaglutide (Wegovy) Market, 2021 - 2033 (USD Million)
Fig. 17 Liraglutide (Saxenda) Market, 2021 - 2033 (USD Million)
Fig. 18 Approved for Other Indications but Used Off-Label for Weight Loss Market, 2021 - 2033 (USD Million)
Fig. 19 Semaglutide (Ozempic) Market, 2021 - 2033 (USD Million)
Fig. 20 Tirzepatide (Mounjaro) Market, 2021 - 2033 (USD Million)
Fig. 21 Dulaglutide (Trulicity) Market, 2021 - 2033 (USD Million)
Fig. 22 oral semaglutide (Rybelsus) Market, 2021 - 2033 (USD Million)
Fig. 23 Oral GLP-1 & Incretin Therapies (Expected Market Entry) Market, 2021 - 2033 (USD Million)
Fig. 24 Oral Semaglutide (50 mg obesity dose) - expected 2026-2027 Market, 2021 - 2033 (USD Million)
Fig. 25 Orforglipron (non-peptide oral GLP-1 RA) - expected 2027-2028 Market, 2021 - 2033 (USD Million)
Fig. 26 Amycretin (oral GLP-1 analog) - pipeline (forecast scenario) Market, 2021 - 2033 (USD Million)
Fig. 27 Dual / Multi-Agonists (High-Impact Future Therapies) Market, 2021 - 2033 (USD Million)
Fig. 28 Tirzepatide (Zepbound) - Injectable (obesity approved US; UK expected) Market, 2021 - 2033 (USD Million)
Fig. 29 Retatrutide - Injectable (GLP 1/GIP/Glucagon triple agonist) Market, 2021 - 2033 (USD Million)
Fig. 30 Cagrisema (Cagrilintide + Semaglutide) - Injectable Market, 2021 - 2033 (USD Million)
Fig. 31 Survodutide (BI 456906) - Injectable (GLP 1/Glucagon dual agonist) Market, 2021 - 2033 (USD Million)
Fig. 32 Pemvidutide - Injectable (GLP-1/Glucagon) Market, 2021 - 2033 (USD Million)
Fig. 33 Non-Incretin Prescription Weight Loss Agents (Approved + generics + centrally acting agents) Market, 2021 - 2033 (USD Million)
Fig. 34 Lipase Inhibitors (Orlistat) Market, 2021 - 2033 (USD Million)
Fig. 35 Centrally Acting Agents (Bupropion/Naltrexone (Mysimba) - licensed in EU/UK for WL) Market, 2021 - 2033 (USD Million)
Fig. 36 Injectable Weight Loss Medications Market, 2021 - 2033 (USD Million)
Fig. 37 Oral Weight Loss Medications Market, 2021 - 2033 (USD Million)
Fig. 38 Public (NHS) Market, 2021 - 2033 (USD Million)
Fig. 39 NHS Primary Care Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 40 NHS Specialist / Hospital Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 41 Private Market, 2021 - 2033 (USD Million)
Fig. 42 Private (In-clinic) Prescriptions Market, 2021 - 2033 (USD Million)
Fig. 43 Digital / Online Prescribing Platforms Market, 2021 - 2033 (USD Million)
Fig. 44 Company categorization
Fig. 45 Company market position analysis
Fig. 46 Strategic framework
